{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-001556","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.701295+00:00","generated_at":"2026-06-07T03:06:23.732229+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Theravance Biopharma Phase 4 PIFR-2 study of YUPELRI fails to meet primary endpoint vs Spiriva HandiHaler in severe COPD","bullets":["PIFR-2 study did not show statistically significant difference on primary endpoint (change in trough FEV1 at Day 85) for YUPELRI vs Spiriva HandiHaler.","Both arms demonstrated similar lung function improvement; YUPELRI safety and tolerability consistent with prior studies.","Study enrolled adults with severe to very severe COPD (FEV1 <50% predicted) and suboptimal PIFR (<55 L/min).","CEO Rick E Winningham noted growth opportunities ahead for YUPELRI, an important COPD maintenance option."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-001556","json":"https://secwatch.observer/filing/0001104659-24-001556.json","markdown":"https://secwatch.observer/filing/0001104659-24-001556.md","text":"https://secwatch.observer/filing/0001104659-24-001556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924001556/0001104659-24-001556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924001556/tm242154d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:06:23.732229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}